R Gabathuler

Biography

Dr Gabathuler obtained his PhD in Biochemistry at the Université de Lausanne, Switzerland, in 1982. He completed postdoctoral studies at the University of Washington, Seattle, WA, USA (1982-1985). He then went to the Swiss Institute for Cancer Research (ISREC) in Lausanne (1985-1987).Following his experience in Lausanne, he took a research position in the newly formed Ludwig Institute for Cancer Research at the Karolinska Institute in Stockholm (1987-1991) pursuing his interest in the regulation of intracellular transport of receptors and proteins. He characterized the regulation of the expression of MHC Class I molecules in cancer cells and virus infected cells. In 1991, he took a research position at the Biotechnology Laboratory at the University of British Columbia in Vancouver, Canada. He developed and reconstituted immuno-recognition of cancer cells after introducing expression of TAP molecules. Dr Gabathuler joined AngioChem Inc. in 2004 as its Chief Scientific Officer and has applied his extensive knowledge in biochemistry, cell biology, and immunology to directing the R&D programs, advancing the company’s first product (ANG1005 now GRN1005) to IND application and into the clinic. Dr Gabathuler obtained his PhD in Biochemistry at the Université de Lausanne, Switzerland, in 1982. He completed postdoctoral studies at the University of Washington, Seattle, WA, USA (1982-1985). He then went to the Swiss Institute for Cancer Research (ISREC) in Lausanne (1985-1987).Following his experience in Lausanne, he took a research position in the newly formed Ludwig Institute for Cancer Research at the Karolinska Institute in Stockholm (1987-1991) pursuing his interest in the regulation of intracellular transport of receptors and proteins. He characterized the regulation of the expression of MHC Class I molecules in cancer cells and virus infected cells. In 1991, he took a research position at the Biotechnology Laboratory at the University of British Columbia in Vancouver, Canada. He developed and reconstituted immuno-recognition of cancer cells after introducing expression of TAP molecules. Dr Gabathuler joined AngioChem Inc. in 2004 as its Chief Scientific Officer and has applied his extensive knowledge in biochemistry, cell biology, and immunology to directing the R&D programs, advancing the company’s first product (ANG1005 now GRN1005) to IND application and into the clinic.

Research Interest

Business Development and Management